S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year

FS Development (FSDC) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

FSDC vs. ANL, ATAI, ANRO, ADCT, CRBP, PEPG, MREO, ORGO, NLTX, and HRTX

Should you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Adlai Nortye (ANL), Atai Life Sciences (ATAI), Alto Neuroscience (ANRO), ADC Therapeutics (ADCT), Corbus Pharmaceuticals (CRBP), PepGen (PEPG), Mereo BioPharma Group (MREO), Organogenesis (ORGO), Neoleukin Therapeutics (NLTX), and Heron Therapeutics (HRTX). These companies are all part of the "medical" sector.

FS Development vs.

FS Development (NASDAQ:FSDC) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.

Adlai Nortye received 4 more outperform votes than FS Development when rated by MarketBeat users.

CompanyUnderperformOutperform
FS DevelopmentN/AN/A
Adlai NortyeOutperform Votes
4
100.00%
Underperform Votes
No Votes

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FS DevelopmentN/AN/AN/AN/AN/A
Adlai NortyeN/AN/AN/AN/AN/A

89.8% of FS Development shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
FS DevelopmentN/A N/A N/A
Adlai Nortye N/A N/A N/A

Adlai Nortye has a consensus price target of $30.00, indicating a potential upside of 181.69%. Given Adlai Nortye's higher possible upside, analysts clearly believe Adlai Nortye is more favorable than FS Development.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FS Development
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Adlai Nortye
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, FS Development had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 2 mentions for FS Development and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.94 beat FS Development's score of 0.00 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
FS Development
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Adlai Nortye
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Adlai Nortye beats FS Development on 4 of the 6 factors compared between the two stocks.

Get FS Development News Delivered to You Automatically

Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FSDC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FSDC vs. The Competition

MetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$375.73M$6.46B$4.80B$7.48B
Dividend YieldN/A3.13%2.99%4.00%
P/E RatioN/A7.21180.9614.13
Price / SalesN/A306.592,419.1489.07
Price / CashN/A29.1046.9034.88
Price / BookN/A5.424.584.19
Net IncomeN/A$141.35M$103.64M$214.15M

FS Development Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANL
Adlai Nortye
1.7714 of 5 stars
$10.80
-12.3%
$30.00
+177.8%
N/A$398.52MN/A0.00130Gap Down
High Trading Volume
ATAI
Atai Life Sciences
2.9605 of 5 stars
$2.39
-8.1%
$10.50
+339.3%
-5.0%$396.81M$310,000.00-8.24133Short Interest ↑
Gap Down
ANRO
Alto Neuroscience
1.5263 of 5 stars
$14.73
+3.7%
$32.33
+119.5%
N/A$395.94MN/A0.00N/APositive News
ADCT
ADC Therapeutics
2.2699 of 5 stars
$4.78
-6.1%
$7.50
+56.9%
+106.5%$394.49M$69.56M-1.63273Short Interest ↑
Analyst Revision
News Coverage
CRBP
Corbus Pharmaceuticals
4.4276 of 5 stars
$37.47
-6.7%
$52.00
+38.8%
+204.4%$393.81M$880,000.00-3.6119
PEPG
PepGen
2.143 of 5 stars
$12.14
-1.8%
$24.67
+103.2%
+1.8%$392.78MN/A-3.6764
MREO
Mereo BioPharma Group
1.3253 of 5 stars
$3.13
-1.3%
$6.50
+107.7%
+136.6%$391.22M$10M0.0036
ORGO
Organogenesis
3.8771 of 5 stars
$2.92
-1.7%
$4.83
+65.5%
+43.7%$385.32M$433.14M73.02862Positive News
NLTX
Neoleukin Therapeutics
0 of 5 stars
$40.96
-1.6%
$30.00
-26.8%
+97.4%$384.94MN/A-13.177
HRTX
Heron Therapeutics
3.6491 of 5 stars
$2.80
+1.8%
$5.00
+78.6%
+1.1%$420.92M$127.04M-3.26126Gap Down

Related Companies and Tools

This page (NASDAQ:FSDC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners